Global Epidermolysis Bullosa Care and Treatment Market: Market Research by Knowledge Sourcing Intelligence
The global Epidermolysis Bullosa market is projected to grow from US$1,313.346 million in 2017 to US$1,644.712 million in 2022, at a compound annual growth rate (CAGR) of 4.60% over the forecast period. Rising expenditure on the treatment of EB and research activities is further propelling the growth of Epidermolysis Bullosa Care and Treatment market. Owing to the increased cases of patients suffering from EB, international organizations, as well as international and domestic banks and financial institutions, are funding global healthcare and pharmaceutical companies to continue the R&D processes for the development of cures and treatments for orphan and rare diseases. In October 2016, the U.S. Food and Drug Administration (FDA) awarded 21 new clinical trial research grants through the Orphan Products Clinical Trials Grants Program. The grant, of more than US$23 million, was awarded to principal investigators from academia and industry for the next four years to promote early and late-stage research and development of treatments and products related to rare diseases.
In December 2016, Amryt Pharma secured a US$21 million loan from the European Investment Bank (EIB) to fund a pivotal trial of its lead candidate AP 102 in Epidermolysis Bullosa. Furthermore, companies are collaborating with each other to gain access to more funds and technological advancements. Recently in July 2017, InMed Pharmaceuticals entered R&D collaboration with ATERA SAS, France-based leading tissue engineering company specializing in the development of advanced human tissue models. The agreement includes the development of 3D human skin models of EB by ATERA to evaluate the in-vitro drug efficacy of InMed’s lead compound INM-750 targeted as a therapy in EB and other potential dermatological and wound-healing applications.
 |
| Sample View of Global Epidermolysis Bullosa Care and Treatment Market Forecast |
Global Epidermolysis Bullosa Care and Treatment Market by Treatment Type:
Epidermolysis Bullosa pharmacological drugs market segment is expected to reach US$394.731 million by 2022, increasing from US$277.200 million in 2016. During this period the market is expected to grow at a high CAGR of 6.07%. At present no cure for the disease exists but several medications to help in alleviating the pain and itching to an extent. These medications are used to reduce itching, pain, and infections. If the condition worsens, antibiotics are prescribed to the patients showing signs of fever, swollen lymph glands, and dysphagia among others.
Global Epidermolysis Bullosa Care and Treatment Market by Geography:
Americas EB Market is projected to grow from US$718.200 million in 2016 to US$964.624 million in 2022, at a compound annual growth rate of 5.04% over the forecast period. for Americas Epidermolysis Bullosa market North America and South America regions together account. The market research provides a detailed analysis of global epidermolysis bullosa care and treatment market on the basis of the various segment like- by geography, by treatment type, etc.
Request Free Sample or Download the report:
For our Healthcare Industry coverage:
The disease usually occurs at birth or in a short while after that. Prevalence is usually subject to age grouping and ethnicity and regional analysis in cross-sectional studies as males and females are equally affected by it.
Comments
Post a Comment